Immix Biopharma, Inc. — Director's Dealing 2021

Dec 16, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Immix Biopharma, Inc. (IMMX)
CIK: 0001873835
Period of Report: 2021-12-15

Reporting Person: Ross Graham (CMO & Head of Clinical Dev.)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options (right to purchase)	$1.86	2031-07-05	Common Stock (15000)		Direct

Footnotes

F1: On July 5, 2021, the Registrant issued the Reporting Person options to purchase up to 15,000 shares of the Registrant's common stock (the "Options"). The Options vest in 48 monthly installments with the first installment vesting on July 5, 2021, subject to the Reporting Person's continued service with the Registrant.